Review Special Issues

Role of sphingosine 1-phosphate (S1P) and effects of fingolimod, an S1P receptor 1 functional antagonist in lymphocyte circulation and autoimmune diseases

  • Sphingosine 1-phosphate (S1P), a multi-functional phospholipid mediator, is generated from sphingosine by sphingosine kinases and binds to five known G protein-coupled S1P receptors (S1P1, S1P2, S1P3, S1P4, and S1P5). It is widely accepted that S1P receptor 1 (S1P1) plays an essential role in lymphocyte egress from the secondary lymphoid organs (SLO) and thymus, because lymphocyte egress from these organs to periphery is at extremely low levels in mice lacking lymphocytic S1P1. Fingolimod hydrochloride (FTY720) is a first-in-class, orally active S1P1 functional antagonist which was discovered by chemical modification of a natural product, myriocin. Since FTY720 has a structure closely related to sphingosine, the phosphorylated FTY720 (FTY720-P) is converted by sphingosine kinases and binds 4 types of S1P receptors. FTY720-P strongly induces down-regulation of S1P1 by internalization and degradation of this receptor and acts as a functional antagonist at S1P1. Consequently, FTY720 inhibits S1P1-dependent lymphocyte egress from the SLO and thymus to reduce circulating lymphocytes including autoreactive Th17 cells, and is highly effective in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). In relapsing remitting MS patients, oral FTY720 shows a superior efficacy when compared to intramuscular interferon-β-1a. Based on these data, it is presumed that modulation of the S1P-S1P1 axis provides an effective therapy for autoimmune diseases including MS.

    Citation: Kenji Chiba, Yasuhiro Maeda, Noriyasu Seki, Hirotoshi Kataoka, Kunio Sugahara. Role of sphingosine 1-phosphate (S1P) and effects of fingolimod, an S1P receptor 1 functional antagonist in lymphocyte circulation and autoimmune diseases[J]. AIMS Molecular Science, 2014, 1(4): 162-182. doi: 10.3934/molsci.2014.4.162

    Related Papers:

    [1] Jiani Jin, Haokun Qi, Bing Liu . Hopf bifurcation induced by fear: A Leslie-Gower reaction-diffusion predator-prey model. Electronic Research Archive, 2024, 32(12): 6503-6534. doi: 10.3934/era.2024304
    [2] Maurıicio F. S. Lima, Jaume Llibre . Hopf bifurcation for a class of predator-prey system with small immigration. Electronic Research Archive, 2024, 32(7): 4604-4613. doi: 10.3934/era.2024209
    [3] Jialu Tian, Ping Liu . Global dynamics of a modified Leslie-Gower predator-prey model with Beddington-DeAngelis functional response and prey-taxis. Electronic Research Archive, 2022, 30(3): 929-942. doi: 10.3934/era.2022048
    [4] Ruizhi Yang, Dan Jin . Dynamics in a predator-prey model with memory effect in predator and fear effect in prey. Electronic Research Archive, 2022, 30(4): 1322-1339. doi: 10.3934/era.2022069
    [5] Yujia Xiang, Yuqi Jiao, Xin Wang, Ruizhi Yang . Dynamics of a delayed diffusive predator-prey model with Allee effect and nonlocal competition in prey and hunting cooperation in predator. Electronic Research Archive, 2023, 31(4): 2120-2138. doi: 10.3934/era.2023109
    [6] Yuan Tian, Hua Guo, Wenyu Shen, Xinrui Yan, Jie Zheng, Kaibiao Sun . Dynamic analysis and validation of a prey-predator model based on fish harvesting and discontinuous prey refuge effect in uncertain environments. Electronic Research Archive, 2025, 33(2): 973-994. doi: 10.3934/era.2025044
    [7] Xianyi Li, Xingming Shao . Flip bifurcation and Neimark-Sacker bifurcation in a discrete predator-prey model with Michaelis-Menten functional response. Electronic Research Archive, 2023, 31(1): 37-57. doi: 10.3934/era.2023003
    [8] Yuan Tian, Yang Liu, Kaibiao Sun . Complex dynamics of a predator-prey fishery model: The impact of the Allee effect and bilateral intervention. Electronic Research Archive, 2024, 32(11): 6379-6404. doi: 10.3934/era.2024297
    [9] Xuemin Fan, Wenjie Zhang, Lu Xu . Global dynamics of a predator-prey model with prey-taxis and hunting cooperation. Electronic Research Archive, 2025, 33(3): 1610-1632. doi: 10.3934/era.2025076
    [10] Yichao Shao, Hengguo Yu, Chenglei Jin, Jingzhe Fang, Min Zhao . Dynamics analysis of a predator-prey model with Allee effect and harvesting effort. Electronic Research Archive, 2024, 32(10): 5682-5716. doi: 10.3934/era.2024263
  • Sphingosine 1-phosphate (S1P), a multi-functional phospholipid mediator, is generated from sphingosine by sphingosine kinases and binds to five known G protein-coupled S1P receptors (S1P1, S1P2, S1P3, S1P4, and S1P5). It is widely accepted that S1P receptor 1 (S1P1) plays an essential role in lymphocyte egress from the secondary lymphoid organs (SLO) and thymus, because lymphocyte egress from these organs to periphery is at extremely low levels in mice lacking lymphocytic S1P1. Fingolimod hydrochloride (FTY720) is a first-in-class, orally active S1P1 functional antagonist which was discovered by chemical modification of a natural product, myriocin. Since FTY720 has a structure closely related to sphingosine, the phosphorylated FTY720 (FTY720-P) is converted by sphingosine kinases and binds 4 types of S1P receptors. FTY720-P strongly induces down-regulation of S1P1 by internalization and degradation of this receptor and acts as a functional antagonist at S1P1. Consequently, FTY720 inhibits S1P1-dependent lymphocyte egress from the SLO and thymus to reduce circulating lymphocytes including autoreactive Th17 cells, and is highly effective in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). In relapsing remitting MS patients, oral FTY720 shows a superior efficacy when compared to intramuscular interferon-β-1a. Based on these data, it is presumed that modulation of the S1P-S1P1 axis provides an effective therapy for autoimmune diseases including MS.


    Abbreviations: FFIDDCs: fuzzy fractional implicit delay differential coupled systems; TFFs: triangular fuzzy functions; MDs: membership degrees; IVP: initial value problem; FDDEs: fuzzy delay differential equations; FDEs: fractional differential equations; DFDEs: fractional differential equations with time delay; FFDEs: fuzzy fractional differential equations; FCFDIVP: fuzzy coupled fractional initial value problem with delays; MF: membership function; TFN: triangular fuzzy number

    In an ecosystem, there exist universally competitions between two species, which is very important. And they tend to interact with each other so that there are some relationships such as predation or symbiosis among them (i.e. coupled systems) (see [9,39]). In addition, the delay and ambiguity may appear because of different reasons such as physical properties of equipment used in the system, signal transmission or measurement of system variables (see [14]), so we need to take them into account. Thus, in this paper, motivated by the work of Dong et al. [13] and Fatullayev et al. [14], we come up with the following problem of fuzzy fractional implicit delay differential coupled systems (FFIDDCs):

    $ {cDαx(t)=m1(t)y(tτ)+~F1(t,y(t),cDαx(t)),t>0,cDβy(t)=m2(t)x(tτ)+~F2(t,x(t),cDβy(t)),t>0,x(t)=~Φ1(t),τt0,y(t)=~Φ2(t),τt0,
    $
    (1.1)

    and explore existence and uniqueness result of solution for the FFIDDC (1.1), where $ ^{c}D^{\alpha}f(t) $ denotes $ \alpha $-order Caputo fractional derivative of function $ f(t)\in C_\alpha^1 $ for $ 0 < \alpha < 1 $ (see [22]), $ \tau $ is the value of time delay, $ \widetilde{\Phi_{1}}(t) $ and $ \widetilde{\Phi_{2}}(t) $ are triangular fuzzy functions (TFFs) defined on $ [-\tau, 0] $, $ \widetilde{F_{1}}(t, y(t), ^{c}D^{\alpha}x(t)) $ and $ \widetilde{F_{2}}(t, x(t), ^{c}D^{\beta}y(t)) $ are also TFFs defined on $ (0, \infty)\times {\mathbb R} \times {\mathbb R} $, and $ m_{1}(t) $ and $ m_{2}(t) $ are continuous crisp functions. The concept of TFFs used in this paper was first proposed by Gasilov et al. [17], then it has been widely employed [7,16,27]. Unlike in the past, Gasilov et al. [17] thought that a fuzzy function is a fuzzy bunch of real functions rather than a fuzzy number-valued function. Each of these real functions has a certain membership degree. The new concept of TFFs broadened the way (see [14]), and so we deal with fuzzy functions and fuzzy problems.

    Remark 1.1. In this paper, we consider the problem with Caputo fractional derivative, which is based on Riemann-Liouville fractional derivative [22]. We note that for temporal variable, the Caputo fractional derivative has been widely recognized in real application. For example, the Caputo fractional derivative of a constant is $ 0 $, but in the case of finite number at the lower limit of the interval, the Riemann-Liouville fractional derivative of a constant is not equal to $ 0 $. And the initial conditions given by Riemann-Liouville method cannot be explained physically. For more related work, see [28,34]. However, can one discuss the existence and uniqueness results for the solutions of the FFIDDC (1.1) with Riemann-Liouville fractional derivative or Hadamard fractional derivative? These are usually presented as important and significative problems in future research.

    Some special cases of the FFIDDC (1.1) are listed as follows:

    (i) If $ \tau = 0, 0\leq t\leq 1 $ and $ \alpha_{j} = 1 $, where $ \alpha_{j} $ is the membership degrees (MDs) of $ \widetilde{F_{j}} $ for $ j = 1, 2 $, the FFIDDC (1.1) can be rewritten as the problem investigated by Dong et al. [13]:

    $ {cDαx(t)=f(t,y(t),cDαx(t)),0t1,cDβy(t)=g(t,x(t),cDβy(t)), 0t1,x(0)=x(0),y(0)=y(0).
    $

    Making full use of fixed point theorem and the vector form of Gronwall inequality, Dong et al. [13] gained existence and uniqueness of solution to the initial value problem (IVP), and discussed the estimation of the solution.

    (ii) If $ \alpha = \beta = 1 $, the FFIDDC (1.1) reduces to the following fuzzy implicit delay differential coupled systems:

    $ {x(t)=m1(t)y(tτ)+~F1(t,y(t),x(t)),t>0,y(t)=m2(t)x(tτ)+~F2(t,x(t),y(t)),t>0,x(t)=~Φ1(t),τt0,y(t)=~Φ2(t),τt0,
    $
    (1.2)

    which is brand new and is worth studying in the future.

    We note that the system (1.2) is an extension of the linear inhomogeneous fuzzy delay differential equations (FDDEs) considered by Fatullayev et al. [14]:

    $ {x(t)=n(t)x(t)+m(t)x(tτ)+˜F(t),t>0,x(t)=˜Φ(t),τt0.
    $

    The authors presented a method to represent the solution of FDDE as a fuzzy set of real functions, and proved existence and uniqueness of solution for FDDE involving TFFs. Furthermore, Fatullayev et al. [14] showed clearly that the proposed method can be extended to the system of FDDEs by using the research results of Gasilov and Amrahov [15]. The purpose of this paper is to discuss existence and uniqueness of solution for the FFIDDC (1.1).

    Comparing with the simpler integer-order differential equations, fractional differential equations (FDEs) have more wide applications and play an important role in engineering, physics, finance and other fields. Nowadays, FDEs have been used to more accurately describe the dynamics of many systems when several complex phenomena in numerous seemingly diverse and widespread fields of science and engineering is modeled and investigated. See, for example, [3,6,22,28,34] and references therein. In addition, to study ecosystem problems in biology, one often discovers that an ecosystem does not have only a single species. That is to say, there must be multiple species, so there exists competition among them and coupling is taken into account (see [9,39]). Coupling relationship refers to the interaction and mutual influence between two or more objects. In fact, the coupled systems of FDEs have been studied by multitudinous researchers. See, for example, [2,38] and the references cited therein. Recently, by applying standard fixed point theorems for multivalued maps, existence of solutions for coupled systems of fractional differential inclusions with coupled boundary conditions was obtained by Ahmad et al. [5].

    In science and engineering and other practical applications, time delay usually occurs on account of manual measurement, signal transmission, aging of equipments and so on (see [30]). Thereby, in recent years, the scholars have been interested in solving the fractional differential equations with time delay (DFDEs) (see, for instance, [30,35] and the references therein). Brzdek and Eghbali [10] considered the Ulam's stability of DFDEs and also proved that under some appropriate assumptions, each approximate solution of DFDEs is close to its only exact solution. In order to acquire existence of solutions for a time dependent delay differential equation with constant delay, Tabassum et al. [33] extended the previous approaches about fuzzy weakly contraction mapping principle. Of course, there are not just one type of FDEs, whether they are linear or nonlinear. And the common ones are Caputo type, Riemann-Liouville type and Hadamard type (see [11,21,36]). Moreover, the delay is not necessarily finite, it can be also infinite. Some researchers dedicated themselves to the study of FDEs with infinite delay. Banach fixed point theorem and the nonlinear alternative of Leray-Schauder type initiated by Granas and Dugundji [18], had been utilized by Benchohra et al. [8] to investigate existence results of FDEs with infinite delay.

    Certainly, in actual application, there are not only time delay, but also exists the possibility of ambiguity. Thus, one needs to take the fuzzy into account, and then the fuzzy fractional differential equations (FFDEs) are proposed. Agarwal et al. [1] put forward a notion of fuzzy Riemann-Liouville differentiability based on Hukuhara differentiability, which can be employed to solve the IVPs of FFDEs. After that, many investigators have extended the concepts and expression forms of FFDEs, and bent themselves to obtain existence and uniqueness of solution for FFDEs. These theories are also well applied in real life. See, for example, [24,25,29] and the references therein. As Fatullayev et al. [14] pointed out, "the types of fuzzy items are more important than their numbers when a fuzzy problem needs to be solved". In fact, we can easily deal with $ n $-th order homogeneous linear differential equations with fuzzy initial values (i.e. the problem with $ n $ fuzzy inputs) by using Zadeh's extension principle. But if a fuzzy forcing function appears in the problem, even for the delay differential equation of first order (i.e. with 2 fuzzy inputs), it will be indistinct how to use the principle.

    It is well know that explicit equations are special cases of implicit equations, and the implicit equations are more general (see [12]). Cubiotti and Yao [12] introduced and studied a class of implicit second-order ordinary differential equations with known endpoint values. They also proved existence results under two conditions. However, as Hoa and Vu [21] stated briefly, "to the best of our knowledge, there exists no literature devoted to the uncertain fractional implicit differential equation in the fuzzy setting with the concepts of Riemann-Liouville, Caputo, Hadamard fractional derivatives". And then, Hoa and Vu [21] proposed some existence results for solutions of the fuzzy fractional implicit differential equations associated with the fuzzy Caputo-type, fuzzy Riemann-Liouville-type and fuzzy Hadamard-type concepts of fractional derivative, respectively. Very recently, Son and Dong [31] proposed global existence and some properties of solutions for the nonlocal problem of implicit fuzzy fractional differential systems. For more work on various forms of implicit FDE models, one can refer to [26,19,20] and the references therein.

    The major methods of this paper are as follows:

    (i) We generalize TFF (Definition 2.1 of [17]) to a group of TFFs (see Example 2.1).

    (ii) To solve the FFIDDC (1.1), we use the method of steps proposed by Fatullayev et al. [14]. Firstly, we figure out the solution of the FFIDDC (1.1) on interval $ [0, \tau] $. Afterwards, we similarly find the solution on interval $ [\tau, 2\tau] $. And as we go along, eventually, the solution on interval $ [0, +\infty) $ can be obtained.

    (iii) Because of the fuzzy coupled fractional initial value problem with delays (FCFDIVP) (3.1), which is the identical transformation of the FFIDDC (1.1), is linear, the superposition principle can be used to work out it. As a consequence, we can decompose the FCFDIVP (3.1) into three subproblems (3.4)-(3.6) and solve them separately.

    The remainder of this paper is organized as follows. The necessary preliminaries about the fuzzy theory that we are going to use are listed in Section 2. In Section 3, we introduce the concept of solution for the FFIDDC (1.1) and describe how to get it. Ultimately, a solution algorithm is proposed. In Section 4, we present an example to show that the hypotheses in all theorems can be met. Finally, in Section 5, we summarize the research results of this paper, and provide the content that one can study in the future.

    Based on the work of Zadeh [37], we define a fuzzy set $ \widetilde{A} $ as a pair of the universal set $ U $ and the membership function (MF) $ \mu:U\rightarrow[0, 1] $. The MF of a fuzzy set $ \widetilde{A} $ can be denoted as $ \mu_{\widetilde{A}} $. For each $ x\in U $, the numerical value $ \mu_{\widetilde{A}}(x) $ is called the MD of $ x $ in $ \widetilde{A} $. The crisp set $ supp(\widetilde{A}) = \{x\in U\mid\mu_{\widetilde{A}}(x) > 0\} $ is called the support of $ \widetilde{A} $.

    After that, let $ U $ be the set of real numbers $ {\mathbb R} $, and $ a, c $ and $ b $ be real numbers which meet $ a\leq c\leq b $. Then the set $ \widetilde{u} $ with MF

    $ μ(x)={xaca, a<x<c,1,x=c,bxbc, c<x<b,0,otherwise
    $

    is called a triangular fuzzy number (TFN) and we denote it as $ \widetilde{u} = (a, c, b) $. On the grounds of the geometric interpretation, the number $ c $ is called the vertex of $ \widetilde{u} $, we denote $ \underline{u} = a $ and $ \overline{u} = b $ to represent the left and the right end-points of $ \widetilde{u} $, respectively. Frequently, we express $ \widetilde{u} = (a, c, b) $ as $ \widetilde{u} = u_{cr}+\widetilde{u}_{un} $. Here, $ u_{cr} = c $ is the crisp part and $ \widetilde{u}_{un} = (a-c, 0, b-c) $ is the uncertain part of $ \widetilde{u} $.

    It is also useful to represent the fuzzy sets though their $ \alpha $-$ cuts $. For each $ \alpha\in(0, 1] $, the crisp set $ A_{\alpha} = \{x\in U\mid \mu_{\widetilde{A}}(x)\geq \alpha\} $ is called the $ \alpha $-$ cut $ of $ \widetilde{A} $. For $ \alpha = 0 $, the $ A_{0} = closure(supp(\widetilde{A})) $.

    For the TFN $ \widetilde{u} = (a, c, b) $, the $ \alpha $-$ cuts $ are intervals $ u_{\alpha} = [\underline{u_{\alpha}}, \overline{u_{\alpha}}] $, where $ \underline{u_{\alpha}} = a+\alpha(c-a) $ and $ \overline{u_{\alpha}} = b+\alpha(c-b) $. These formulas can be rewritten as $ \underline{u_{\alpha}} = c+(1-\alpha)(a-c) $ and $ \overline{u_{\alpha}} = c+(1-\alpha)(b-c) $. Therefore, $ u_{\alpha} = [\underline{u_{\alpha}}, \overline{u_{\alpha}}] = c+(1-\alpha)[a-c, b-c] $. From here we can see that an $ \alpha $-$ cut $ is homothetic to $ [a, b] $ (which is the $ 0 $-$ cut $) with center $ c $ and with ratio $ (1-\alpha) $.

    There are different notions about the fuzzy functions. In this study, we use the concept of the fuzzy function which was brought forward by Gasilov et al. [17], namely, fuzzy function is a bunch of fuzzy real functions. As a value $ \widetilde{F}(t) $ of a fuzzy bunch $ \widetilde{F} $ at time $ t $, we understand the fuzzy set, which elements are the values of the real functions at $ t $, with the higher MD of the corresponding functions. Mathematically,

    $ μ˜F(t)(x)=α  y():(μ˜F(y)=αy(t)=x)z():(μ˜F(z)>αz(t)x),
    $

    where "$ \wedge $" and "$ \rightarrow $" are the logical conjunction and implication symbols, respectively.

    Definition 2.1. ([17]) Let U be set of continuous functions defined on an interval I, and $ F_{a}(\cdot), F_{c}(\cdot), F_{b}(\cdot)\in U $. We call the fuzzy subset $ \widetilde{F} $ of U, determined by the MF as follows:

    $ μ˜F(y())={α,y=Fa+α(FcFa)and0<α1,α,y=Fb+α(FcFb)and0<α1,0,otherwise,
    $

    as TFF and denote it as $ \widetilde{F} = \langle F_{a}, F_{c}, F_{b}\rangle $.

    According to this definition, a TFF is a fuzzy set (or, fuzzy bunch) of real functions. Among them only two functions have the MD $ \alpha $: the functions $ y_{1} = F_{a}+\alpha(F_{c}-F_{a}) $ and $ y_{2} = F_{b}+\alpha(F_{c}-F_{b}) $.

    Referring to the example of TFF given by Gasilov et al. [16], we give the following example of a group of TFFs.

    Example 2.1. In Figure 1, we depict a group of TFFs as

    Figure 1.  A group of TFFs.
    $ {~F1=F1a,F1c,F1b~F2=F2a,F2c,F2b
    $

    where

    $ F_{1a}(t) = -t^{2}+5\, t-4 $ $($MD is $ 0 $, the black curve that is at bottom on $ [0, 1] $ and at upper on $ [1,2] )$;

    $ F_{1c}(t) = 0.5\, t^{2}-1.5\, t+1 $ $($MD is $ 1 $, the black dashed line);

    $ F_{1b}(t) = t^{2}-5\, t+4 $ $($MD is $ 0 $, the black curve that is at upper on $ [0, 1] $ and at bottom on $ [1,2]) $;

    $ F_{2a}(t) = -2\, t^{2}+4\, t-2 $ $($MD is $ 0 $, the blue curve that is at bottom on $ [0, 2]) $;

    $ F_{2c}(t) = t^{2}-2\, t+1 $ $($MD is $ 1 $, the blue dashed line$)$;

    $ F_{2b}(t) = 2\, t^{2}-4\, t+2 $ $($MD is $ 0 $, the blue curve that is at upper on $ [0, 2]) $.

    The TFF $ \widetilde{F_{1}} $ with MDs $ 0.7 $ and $ 0.3 $ are depicted by red dotted and dashed-dotted lines, respectively. And the TFF $ \widetilde{F_{2}} $ with MDs $ 0.7 $ and $ 0.3 $ are described by cyan dotted and dashed-dotted lines which are marked, respectively.

    The value of a TFF at a time $ t\in I $ can be expressed by the following formula:

    $ ˜F(t)=(min{Fa(t),Fc(t),Fb(t)},Fc(t),max{Fa(t),Fc(t),Fb(t)}).
    $

    We can easily find out that this value is a TFN, and a TFF $ \widetilde{F} = \langle F_{a}, F_{b}, F_{c}\rangle $ is not a fuzzy number-valued function. Actually, it is a fuzzy subset of the universe of continuous functions. Each element of this fuzzy subset is a real function with a certain MD.

    If $ F_{a}(t)\leq F_{c}(t)\leq F_{b}(t) $ for all $ t\in I $, then the TFF $ \widetilde{F} = \langle F_{a}, F_{c}, F_{b}\rangle $ is regular TFF on $ I $, and we have $ \widetilde{F}(t) = (F_{a}(t), F_{c}(t), F_{b}(t)) $. Further, when a TFF $ \widetilde{F} $ is not regular, we call it as non-regular TFF. It means that for a non-regular TFF, in general, $ \widetilde{F}(t)\neq (F_{a}(t), F_{c}(t), F_{b}(t)) $. And the graphs of functions $ F_{a}, F_{c} $ and $ F_{b} $ can interchanged as $ t $ goes. In Figure 1, the TFFs $ \widetilde{F_{1}} $ and $ \widetilde{F_{2}} $ are non-regular and regular on $ [0, 2] $, respectively. Without loss of generality, no matter regular TFFs or non-regular TFFs, main results and the algorithm in this paper are all valid. In the sequel, we assume that TTFs are regular.

    Now, we will consider the FFIDDC (1.1) in this section. With respect to the FFIDDC (1.1), we can solve it by using the method of steps introduced by Fatullayev et al. [14].

    First of all, we deal with the FFIDDC (1.1) on interval $ [0, \tau] $. Because $ x(t-\tau) = \widetilde{\Phi_{1}}(t-\tau), y(t-\tau) = \widetilde{\Phi_{2}}(t-\tau) $ for $ t\in[0, \tau] $, the FFIDDC (1.1) is equivalent to FCFDIVP as follows:

    $ {cDαx(t)=~G1(t,y(t),cDαx(t)),cDβy(t)=~G2(t,x(t),cDβy(t)),x(0)=~Φ1(0),y(0)=~Φ2(0),
    $
    (3.1)

    where

    $ ~G1(t,y(t),cDαx(t))=m1(t)~Φ2(tτ)+~F1(t,y(t),cDαx(t)),~G2(t,x(t),cDβy(t))=m2(t)~Φ1(tτ)+~F2(t,x(t),cDβy(t)).
    $

    Thus, we transform the FCFDIVP (3.1) in matrix form:

    $ {DZ(t)=˜G(),Z(0)=˜Φ(0).
    $
    (3.2)

    Here, $ Z(t) = \left(x(t)y(t)

    \right) $, $ D = \left(cDα00cDβ
    \right) $, $ \widetilde{G}(\cdot) = \left(~G1(t,y(t),cDαx(t))~G2(t,x(t),cDβy(t))
    \right) $ and $ \widetilde{\Phi}(0) = \left(~Φ1(0)~Φ2(0)
    \right). $

    Definition 3.1. For the problem $(3.2)$, the fuzzy set $ \widetilde{Z} $ with MF

    $ μ˜Z(Z())=min{μ˜Φ(ϕ(0)),μ˜G(DZ(t))}
    $
    (3.3)

    is called to be a solution of the problem $(3.2)$, which is also a solution to the FCFDIVP $(3.1)$, where $ \phi(0) = Z(0) $.

    As for the formula (3.3), let $ Z(t) $ be a functional matrix. We determine $ \phi(0) = Z(0) $ for $ t\in[0, \tau] $ and calculate $ \mu_{1}\triangleq \mu_{\widetilde{\Phi}}(\phi(0)) $. After that, we compute $ g(\cdot) = D\cdot Z(t) $ on interval $ [0, \tau] $ and determine $ \mu_{2}\triangleq \mu_{\widetilde{G}}(g(\cdot)) $. Finally, we calculate the MD $ \mu $ as $ \mu = \min\{\mu_{1}, \mu_{2}\} $. We assign the number $ \mu $ as the MD of $ Z(t) $. We define the set of all functional matrices such as $ Z(t) $ with their MDs $ \mu $ as the fuzzy solution $ \widetilde{Z} $.

    According to Definition 3.1., the solution $ \widetilde{Z} $ is a fuzzy bunch of real functional matrices, which consists of functional matrices such as $ Z(t) $. If a functional matrix $ Z(t) $ satisfies

    $ {DZ(t)=g(),Z(0)=ϕ(0)
    $

    for some functional matrices $ g\in supp(\widetilde{G}) $ and $ \phi(0)\in supp(\widetilde{\Phi}(0)) $, then it has a positive MD.

    Let us represent $ \widetilde{G_{1}} = g_{1cr}+\widetilde{g_{1}} $ (crisp part + uncertainty), where $ g_{1cr} = G_{1c} $ and $ \widetilde{g_{1}} = \langle g_{1a}, 0, g_{1b}\rangle = \langle G_{1a}-G_{1c}, 0, G_{1b}-G_{1c}\rangle $. Similarly, $ \widetilde{G_{2}} = g_{2cr}+\widetilde{g_{2}} $, here $ g_{2cr} = G_{2c} $ and $ \widetilde{g_{2}} = \langle g_{2a}, 0, g_{2b}\rangle $.

    Assume that $ \widetilde{\Phi_{1}} $ and $ \widetilde{\Phi_{2}} $ are regular TFFs. Then $ \widetilde{\Phi_{1}}(0) $ and $ \widetilde{\Phi_{2}}(0) $ are TFNs. Further, $ \widetilde{\Phi_{1}}(0) = \phi_{1cr}(0)+\widetilde{\phi_{1}}(0) $, here $ \phi_{1cr}(0) = \Phi_{1c}(0) $ and $ \widetilde{\phi_{1}}(0) = (\phi_{1a}(0), 0, \phi_{1b}(0)) = (\Phi_{1a}(0)-\Phi_{1c}(0), 0, \Phi_{1b}(0)-\Phi_{1c}(0)) $. In the same way, $ \widetilde{\Phi_{2}}(0) = \phi_{2cr}(0)+\widetilde{\phi_{2}}(0) $, here $ \phi_{2cr}(0) = \Phi_{2c}(0) $ and $ \widetilde{\phi_{2}}(0) = (\phi_{2a}(0), 0, \phi_{2b}(0)) $.

    Since the FCFDIVP (3.1) is linear, we can solve it using the superposition principle. This follows that in order to find the solution of the FCFDIVP (3.1), we can separately consider the following subproblems:

    (1) The associated crisp problem:

    $ {cDαx(t)=g1cr(t,y(t),cDαx(t)),cDβy(t)=g2cr(t,x(t),cDβy(t)),x(0)=ϕ1cr(0),y(0)=ϕ2cr(0).
    $
    (3.4)

    (2) The problem with initial TFFs:

    $ {cDαx(t)=0,cDβy(t)=0,x(0)=~ϕ1(0),y(0)=~ϕ2(0).
    $
    (3.5)

    (3) The problem with fuzzy source functions and zero initial functions:

    $ {cDαx(t)=~g1(t,y(t),cDαx(t)),cDβy(t)=~g2(t,x(t),cDβy(t)),x(0)=0,y(0)=0.
    $
    (3.6)

    By solving the above three subproblems (3.4)-(3.6), the solution of the FFIDDC (1.1) on interval $ [0, \tau] $ can be obtained. Similarly, at the next step, we can find the solution on interval $ [\tau, 2\tau] $. Hence, we can conclude that the solution of the FFIDDC (1.1) exists for $ t\in[0, \infty) $ using the method of steps [14].

    In the sequel, we make clear how to solve each of these three subproblems (3.4)-(3.6).

    To solve the problem (3.4), we provide the following theorem.

    Theorem 3.1. For the problem $(3.4)$, we can get a unique solution to it, which is denoted as $ Z_{cr}(t) = \left(xcr(t)ycr(t)

    \right) $, when the following conditions fulfill:

    $ (H_{1}) $ $ g_{1cr}, g_{2cr}: [0, \tau]\times {\mathbb R}\times {\mathbb R}\rightarrow {\mathbb R} $ are continuous.

    $ (H_{2}) $ There exist constants $ K_{i}, L_{i}\in (0, 1) $ for $ i = 1, 2 $ such that

    $ 0 < \max\left\{K_{2}+\dfrac{K_{1}}{\Gamma(\beta+1)}, \, L_{2}+\dfrac{L_{1}}{\Gamma(\alpha+1)}\right\} < 1 $

    and for each $ x_{1}, x_{2}, y_{1}, y_{2}\in {\mathbb R} $,

    $ g1cr(t,x1,y1)g1cr(t,x2,y2)∣≤K1x1x2+K2y1y2,g2cr(t,x1,y1)g2cr(t,x2,y2)∣≤L1x1x2+L2y1y2.
    $

    Proof. The proof is similar to Theorem 3.1 of Dong et al. [13] and it is omitted.

    In this subsection, we will give solvability of the problem (3.5) as follows.

    Theorem 3.2. Consider the problem $(3.5)$, where $ \widetilde{\phi_{1}}(0) = (\phi_{1a}(0), 0, \phi_{1b}(0)), \widetilde{\phi_{2}}(0) = (\phi_{2a}(0), 0, \phi_{2b}(0)) $. If $ Z_{a}(t) = \left(xa(t)ya(t)

    \right) $ and $ Z_{b}(t) = \left(xb(t)yb(t)
    \right) $ are solutions of the problem

    $ {cDαx(t)=0,cDβy(t)=0,x(0)=ϕ1(0),y(0)=ϕ2(0)
    $
    (3.7)

    for $ \left(ϕ1(0)ϕ2(0)

    \right) = \left(ϕ1a(0)ϕ2a(0)
    \right) $ and $ \left(ϕ1(0)ϕ2(0)
    \right) = \left(ϕ1b(0)ϕ2b(0)
    \right) $, respectively, then the problem $(3.5)$ has a unique solution $ \widetilde{Z_{\phi}} $, which is a TFF matrix given by

    $ ~Zϕ=Za,0,Zb.
    $
    (3.8)

    Proof. On the one hand, according to Definition 3.1., it is easy for us to know that each $ Z(t) $ with non-zero MD from the bunch $ \widetilde{Z_{\phi}} $ is a solution of the problem (3.7) for some $ \left(ϕ1(0)ϕ2(0)

    \right) $ from $ \left(~ϕ1(0)~ϕ2(0)
    \right) $.

    On the other hand, in terms of Definition 2.1, the bunch $ \widetilde{\phi_{1}} = \langle \phi_{1a}, 0, \phi_{1b}\rangle $ consists of functions $ k\phi_{1a} $ and $ k\phi_{1b} $ $ \left([0, 1]\ni k = 1-\alpha\right) $ owing to $ \phi_{1c} = 0 $. And the bunch $ \widetilde{\phi_{2}} = \langle\phi_{2a}, 0, \phi_{2b}\rangle $ is similar to the former.

    Moreover, if a Z(t) is a solution of the problem (3.7), then $ kZ(t) $ is a solution of the same equation with $ \left(kϕ1(0)kϕ2(0)

    \right) $ taken instead of $ \left(ϕ1(0)ϕ2(0)
    \right) $.

    From the above reasoning we can get the conclusion that the bunch $ \widetilde{Z_{\phi}} $ consists of $ kZ_{a} $ and $ kZ_{b} $. Therefore, the bunch $ \widetilde{Z_{\phi}} $ is a TFF matrix determined to be $ \widetilde{Z_{\phi}} = \langle Z_{a}, 0, Z_{b}\rangle $.

    Actually, we can get the solutions $ Z_{a}(t) = \left(ϕ1a(0)ϕ2a(0)

    \right) $ and $ Z_{b}(t) = \left(ϕ1b(0)ϕ2b(0)
    \right) $.

    We can express the value of the TFF matrix $ \widetilde{Z_{\phi}} $ (3.8) at a time $ t $ by the formula $ \widetilde{Z_{\phi}}(t) = (\min\{Z_{a}(t), 0, Z_{b}(t)\}, 0, \max\{Z_{a}(t), 0, Z_{b}(t)\}) $. Note that this value is a matrix of TFNs.

    As for the solution of the problem (3.6), we give the theorem as follows.

    Theorem 3.3. In the problem $(3.6)$, assume $ \widetilde{g_{1}} = \langle g_{1a}, 0, g_{1b}\rangle, \widetilde{g_{2}} = \langle g_{2a}, 0, g_{2b}\rangle $, where $ \left(g1ag2a

    \right) $ and $ \left(g1bg2b
    \right) $ separately
    satisfy the conditions $ (H_{1}) $ and $ (H_{2}) $ of Theorem 3.1. If $ Z_{u}(t) = \left(xu(t)yu(t)
    \right) $ and $ Z_{v}(t) = \left(xv(t)yv(t)
    \right) $ are solutions of the following problem:

    $ {cDαx(t)=g1(t,y(t),cDαx(t)),cDβy(t)=g2(t,x(t),cDβy(t)),x(0)=0,y(0)=0
    $
    (3.9)

    for $ \left(g1g2

    \right) = \left(g1ag2a
    \right) $ and $ \left(g1g2
    \right) = \left(g1bg2b
    \right) $ in several, then the problem $(3.6)$ has a unique solution $ \widetilde{Z_{g}} $, which is a TFF matrix given by

    $ ~Zg=Zu,0,Zv.
    $
    (3.10)

    Proof. Since $ g_{1a} $ and $ g_{2a} $ satisfy $ (H_{1}) $ and $ (H_{2}) $, it follows from Theorem 3.1 that there will be a unique solution when $ \left(g1g2

    \right) = \left(g1ag2a
    \right) $ in (3.9). By the same token, from the assumption for $ \left(g1g2
    \right) = \left(g1bg2b
    \right) $ in the problem (3.9), only one solution will exist in this case. Thus, the proof can be done by the same way as in Theorem 3.2.

    Thus, we can also express the value of the TFF matrix $ \widetilde{Z_{g}} $ (3.10) at a time $ t $ by $ \widetilde{Z_{g}}(t) = (\min\{Z_{u}(t), 0, Z_{v}(t)\}, 0, \max\{Z_{u}(t), 0, Z_{v}(t)\}) $, which is a matrix of TFNs.

    By integrating Theorems 3.1-3.3 above, we can obtain the following solution algorithm for solving the FFIDDC (1.1).

    Algorithm 3.1. Step 1. Using the method of steps and dealing with the FFIDDC $(1.1)$ on interval $ [0, \tau] $, transform the FFIDDC $(1.1)$ into the FCFDIVP $(3.1)$.

    Step 2. Represent the initial values and source functions as

    $ ~G1=g1cr+g1a,0,g1b,~G2=g2cr+g2a,0,g2b,~Φ1(0)=ϕ1cr(0)+(ϕ1a(0),0,ϕ1b(0)),~Φ2(0)=ϕ2cr(0)+(ϕ2a(0),0,ϕ2b(0)).
    $

    Step 3. Find the solution $ Z_{cr}(t) $ of the problem $(3.4)$.

    Step 4. Seek the solutions $ Z_{a}(t) $ and $ Z_{b}(t) $ of the problem $(3.7)$ in regard to $ \left(ϕ1(0)ϕ2(0)

    \right) = \left(ϕ1a(0)ϕ2a(0)
    \right) $ and $ \left(ϕ1(0)ϕ2(0)
    \right) = \left(ϕ1b(0)ϕ2b(0)
    \right) $, respectively, and define

    $ ~Zϕ(t)=(min{Za(t),0,Zb(t)},0,max{Za(t),0,Zb(t)}).
    $

    Step 5. Solve the problem $(3.9)$ and denote the solutions by $ Z_{u}(t) $ and $ Z_{v}(t) $, corresponding to $ \left(g1g2

    \right) = \left(g1ag2a
    \right) $ and $ \left(g1g2
    \right) = \left(g1bg2b
    \right) $, respectively, and let

    $ ~Zg(t)=(min{Zu(t),0,Zv(t)},0,max{Zu(t),0,Zv(t)}).
    $

    Step 6. Construct the unique solution of the FFIDDC $(1.1)$ on interval $ [0, \tau] $ as follows:

    $ ˜Z(t)=Zcr(t)+~Zϕ(t)+~Zg(t).
    $

    Similarly, we can find the unique solution on interval $ [\tau, 2\tau] $, $ \cdots $. In consequence, we obtain a unique solution of the FFIDDC (1.1) which exists at $ t\geq 0 $.

    In this section, referring to Example 1 in Fatullayev et al. [14], we take an example to clarify that the hypotheses in Theorems 3.1-3.3 can be satisfied, which can be also employed to verify the main results presented in Dong et al. [13].

    Example 4.1. Let us solve the problem

    $ {cD12x(t)=costy(tπ2)+~F1(t,y(t),cD12x(t)),t>0,cD12y(t)=sintx(tπ2)+~F2(t,x(t),cD12y(t)),t>0,x(t)=~Φ1(t),π2t0,y(t)=~Φ2(t),π2t0,
    $
    (4.1)

    where

    $ ~F1=f1cr+f1a,0,f1b,~F2=f2cr+f2a,0,f2b,~Φ1=ϕ1cr+ϕ1a,0,ϕ1b,~Φ2=ϕ2cr+ϕ2a,0,ϕ2b
    $

    with

    $ f1cr=0.5siny(t)+103sincD12x(t),f2cr=0.7sinx(t)103sincD12y(t),f1a=0.15sintcost, f1b=0.15sintcost,f2a=0.15sintcost,f2b=0.15sintcost,ϕ1cr=cost, ϕ1a=0.15sint0.25cost, ϕ1b=0.15sint+0.25cost,ϕ2cr=sint, ϕ2a=0.15cost0.25sint, ϕ2b=0.15cost+0.25sint.
    $

    In the sequel, we only deal with the problem (4.1) on interval $ \left[0, \dfrac{\pi}{2}\right] $. The unique solution on interval $ [\tau, 2\tau] $, $ \cdots $ can be likewise found.

    Firstly, the problem (4.1) can be transformed as the problem

    $ {cD12x(t)=~G1(t,y(t),cD12x(t)),cD12y(t)=~G2(t,x(t),cD12y(t)),x(0)=~Φ1(0),y(0)=~Φ2(0),
    $
    (4.2)

    where

    $ ~G1(t,y(t),cD12x(t))=cost~Φ2(tπ2)+~F1(t,y(t),cD12x(t)),~G2(t,x(t),cD12y(t))=sint~Φ1(tπ2)+~F2(t,x(t),cD12y(t)).
    $

    Then, after performing some arithmetics, one can get

    $ ~G1=g1cr+g1a,0,g1b,~G2=g2cr+g2a,0,g2b,~Φ1(0)=ϕ1cr(0)+~ϕ1(0),~Φ2(0)=ϕ2cr(0)+~ϕ2(0),
    $

    where

    $ g1cr=cos2t0.5siny(t)+103sincD12x(t),g2cr=sin2t+0.7sinx(t)103sincD12y(t),g1a=0.25cos2t,g1b=0.25cos2t,g2a=0.25sin2t,g2b=0.25sin2t,ϕ1cr(0)=1,~ϕ1(0)=(0.25,0,0.25),ϕ2cr(0)=0,~ϕ2(0)=(0.15,0,0.15).
    $

    Next, we respectively solve the three subproblems of the problem (4.2) on $ \left[0, \dfrac{\pi}{2}\right] $ one by one.

    (i) With respect to $ g_{1cr} $ and $ g_{2cr} $, we can rewrite them in another forms:

    $ g1cr(t,u,v)=cos2t0.5sinu+103sinv,g2cr(t,m,n)=sin2t+0.7sinm103sinn,
    $

    where

    $ u=y(t),v=cD12x(t),m=x(t),n=cD12y(t).
    $

    We can easily see that $ g_{1cr}, g_{2cr}:[0, \dfrac{\pi}{2}]\times {\mathbb R}\times {\mathbb R}\rightarrow {\mathbb R} $ are continuous and satisfy $ (H_{1}) $.

    Moreover, taking $ K_{1} = 0.5 $, $ K_{2} = 10^{-3} $, $ L_{1} = 0.7 $ and $ L_{2} = 10^{-3} $, then we have

    $ max{K2+K1Γ(12+1),L2+L1Γ(12+1)}=max{103+0.5Γ(32),103+0.7Γ(32)}=max{0.5718,0.8000}=0.8000(0,1),
    $

    and

    $ g1cr(t,u1,v1)g1cr(t,u2,v2)∣≤K1u1u2+K2v1v2,g2cr(t,m1,n1)g2cr(t,m2,n2)∣≤L1m1m2+L2n1n2
    $

    for $ i = 1, 2 $ and any $ u_{i} $, $ v_{i} $, $ m_{i} $, $ n_{i}\in {\mathbb R} $. Hence, it is easy to see that $ (H_{2}) $ holds.

    To sum up, all the hypotheses $ (H_{1}) $ and $ (H_{2}) $ in Theorem 3.1 are satisfied and we can obtain a unique solution $ Z_{cr}(t) $, which is illustrated in Figure 2 to the following associated crisp subproblem via using the "L1 method" due to Li and Zeng [23]:

    $ {cD12x(t)=g1cr(t,y(t),cD12x(t))=cos2t0.5siny(t)+103sincD12x(t),cD12y(t)=g2cr(t,x(t),cD12y(t))=sin2t+0.7sinx(t)103sincD12y(t),x(0)=ϕ1cr(0)=1,y(0)=ϕ2cr(0)=0,
    $
    (4.3)
    Figure 2.  The crisp solutions (global).

    which is the first subproblem of the problem (4.2).

    From Figure 2, one can easily see that the order of magnitude of the ordinate value in Figure 2 is $ 10^8 $, and $ x_{cr} $ and $ y_{cr} $ established by relying on the "L1 method" discretization [23] of the Caputo fractional derivatives in (4.3), are growing very fast, and after iterating 43 times ($ t\approx 0.66 $), the values of $ x_{cr} $ and $ y_{cr} $ approach $ 1 $ and $ 27.88 $, respectively. Since the ordinate value of Figure 2 is too large to observe between $ t = 0.6 $ and $ t = 0.7 $, we give the local graph Figure 3 for the crisp discretized solutions to the problem (4.3) on the ordinate value interval $ \left[0, 100\right] $, which right endpoint is far less than that of the ordinate value interval $ [0, 4\times 10^8] $ in Figure 2. We note that Figure 3 locally shows the unique solution $ Z_{cr}(t) = \left(xcr(t)ycr(t)

    \right) = \left(127.88
    \right) $ of the problem (4.3) at $ t\approx 0.66\in \left[0, \dfrac{\pi}{2}\right] $.

    Figure 3.  The crisp solutions (ordinate local interval $ [0, 100] $).

    (ii) Solve the following crisp problem:

    $ {cD12x(t)=0,cD12y(t)=0,x(0)=ϕ1(0),y(0)=ϕ2(0)
    $

    for $ \left(ϕ1(0)ϕ2(0)

    \right) = \left(0.250.15
    \right) $ and $ \left(ϕ1(0)ϕ2(0)
    \right) = \left(0.250.15
    \right) $, and find the solutions $ Z_{a}(t) = \left(0.250.15
    \right) $ and $ Z_{b}(t) = \left(0.250.15
    \right) $, respectively.

    Letting $ \widetilde{\phi_{1}}(0) = (-0.25, 0, 0.25) $ and $ \widetilde{\phi_{2}}(0) = (-0.15, 0, 0.15) $, then it follows that the solution to the second subproblem of the problem (4.2) as hereunder mentioned:

    $ {cD12x(t)=0,cD12y(t)=0,x(0)=~ϕ1(0),y(0)=~ϕ2(0)
    $
    (4.4)

    is the TFF matrix $ \widetilde{Z_{\phi}} = \langle Z_{a}, 0, Z_{b}\rangle $, which is graphed in Figure 4, and one knows that

    $ \widetilde{Z_{\phi}}(t) = \left(\min\{Z_{a}(t), 0, Z_{b}(t)\}, 0, \max\{Z_{a}(t), 0, Z_{b}(t)\}\right). $
    Figure 4.  Uncertainty of the solutions with initial TFFs.

    Hence, Theorem 3.2 holds and there is one and only solution to the problem (4.4). Indeed, since the solutions $ Z_{a}(t) $ and $ Z_{b}(t) $ are all constant matrices in Figure 4, it is easy to see that the values of $ \widetilde{x_{\phi_{1}}} $ and $ \widetilde{y_{\phi_{2}}} $ are all constants when MD $ \alpha\in [0, 1] $ is determined. That is, the values of $ \widetilde{x_{\phi_{1}}} $ and $ \widetilde{y_{\phi_{2}}} $ remain constant as $ t $ increases. For example, $ \widetilde{x_{\phi_{1a}}} = 0.25 $, $ \widetilde{x_{\phi_{1b}}} = -0.25 $, $ \widetilde{y_{\phi_{2a}}} = 0.15 $ and $ \widetilde{y_{\phi_{2b}}} = -0.15 $ when $ \alpha = 0 $.

    (iii) Consider the following crisp problem:

    $ {cD12x(t)=g1(t,y(t),cD12x(t)),cD12y(t)=g2(t,x(t),cD12y(t)),x(0)=0,y(0)=0
    $

    for $ \left(g1g2

    \right) = \left(g1ag2a
    \right) $ and $ \left(g1g2
    \right) = \left(g1bg2b
    \right) $, and find the solutions $ Z_{u}(t) = \left(xu(t)yu(t)
    \right) $ and $ Z_{v}(t) = \left(xv(t)yv(t)
    \right) $, respectively. That is, one solves the following crisp problems:

    $ {cD12x(t)=g1a(t,y(t),cD12x(t))=0.25cos2t,cD12y(t)=g2a(t,x(t),cD12y(t))=0.25sin2t,x(0)=0,y(0)=0
    $
    (4.5)

    and

    $ {cD12x(t)=g1b(t,y(t),cD12x(t))=0.25cos2t,cD12y(t)=g2b(t,x(t),cD12y(t))=0.25sin2t,x(0)=0,y(0)=0.
    $
    (4.6)

    As for the problem (4.5), $ g_{1a} $ and $ g_{2a} $ can be written in following forms:

    $ g1a(t,u,v)=0.25cos2t,g2a(t,m,n)=0.25sin2t,
    $

    where

    $ u=y(t),v=cD12x(t),m=x(t),n=cD12y(t).
    $

    It is clear to find that $ g_{1a}, g_{2a}:[0, \dfrac{\pi}{2}]\times {\mathbb R}\times {\mathbb R}\rightarrow {\mathbb R} $ are continuous.

    On the other hand, let $ K_{1} = 0.4 $, $ K_{2} = 0.1 $, $ L_{1} = 0.6 $ and $ L_{2} = 0.2 $. Then

    $ max{K2+K1Γ(12+1),L2+L1Γ(12+1)}=max{0.1+0.4Γ(32),0.2+0.6Γ(32)}=max{0.5514,0.8770}=0.8770(0,1),
    $

    and for each $ u_{1} $, $ u_{2} $, $ v_{1} $, $ v_{2} $, $ m_{1} $, $ m_{2} $, $ n_{1} $, $ n_{2}\in {\mathbb R} $,

    $ g1a(t,u1,v1)g1a(t,u2,v2)∣≤K1u1u2+K2v1v2,g2a(t,m1,n1)g2a(t,m2,n2)∣≤L1m1m2+L2n1n2.
    $

    According to the above, all the hypotheses $ (H_{1}) $ and $ (H_{2}) $ hold. And that on the basis of Theorem 3.1, we can obtain the unique solution $ Z_{u}(t) $ to the last subproblem of the problem (4.2) involving fuzzy source functions and zero initial functions as follows:

    $ {cD12x(t)=g1a,0,g1b,cD12y(t)=g2a,0,g2b,x(0)=0,y(0)=0.
    $
    (4.7)

    Similarly, we can conclude that the problem (4.6) also has a unique solution $ Z_{v}(t) $. It follows that the solution to the problem (4.7) is the TFF matrix $ \widetilde{Z_{g}} = \langle Z_{u}, 0, Z_{v}\rangle $, which is depicted in Figure 5, and we have

    $ ~Zg(t)=(min{Zu(t),0,Zv(t)},0,max{Zu(t),0,Zv(t)}).
    $
    Figure 5.  Uncertainty of the solutions owing to fuzzy source functions.

    As a consequence, Theorem 3.3 holds and there is a unique solution to the problem (4.7). Moreover, it can be seen that, in Figure 5, the images of $ \widetilde{x_{g_{1}}} $ and $ \widetilde{y_{g_{2}}} $ are respectively symmetric when the corresponding MDs are chosen. For MD $ \alpha\in [0, 1) $, as $ t $ increases, the upper branch of $ \widetilde{x_{g_{1}}} $ firstly increases and then decreases ($ t\approx 0.69 $ is the turning point), and the upper branch of $ \widetilde{y_{g_{2}}} $ gets bigger and bigger. Especially, the values of $ \widetilde{x_{g_{1}}} $ and $ \widetilde{y_{g_{2}}} $ are constant $ 0 $ when the MD $ \alpha = 1 $. However, the ordinate value of Figure 5 is of order of magnitude $ 10^{-1} $ and very small compared with that in Figure 2, so it has little effect on the final solution $ \widetilde{Z}(t) $.

    In conclusion, by solving the problems (4.3), (4.4) and (4.7), it follows from Algorithm 3.1 that we can find the unique solution of the problem (4.1) on interval $ \left[0, \dfrac{\pi}{2}\right] $ as

    $ ˜Z(t)=Zcr(t)+~Zϕ(t)+~Zg(t),
    $

    which can be found from Figure 6. It is easy to note that the image of fuzzy solution $ \widetilde{Z}(t) $ in Figure 6 has a similar trend to that of the crisp solution $ Z_{cr}(t) $ in Figure 2. That is because when MD is fixed, the unique solution $ \widetilde{Z}(t) $ of the problem (4.1) is composed of three parts and the value of the crisp solution $ Z_{cr}(t) $ for the problem (4.3) is too large (order of magnitude $ 10^8 $ of the ordinate value for Figure 2). Further, since the ordinate value of Figure 6 is very big (order of magnitude $ 10^8 $) and the curves of $ \widetilde{x}, \widetilde{y} $ can not be distinguished obviously, a local graph Figure 7 of Figure 6 is given for the fuzzy solutions of the problem (4.1) when the ordinate value interval is restricted to $ \left[0, 30\right] $. Choosing specially MD $ \alpha = 0 $, we have $ \widetilde{x_{\phi_{1a}}} = 0.93 $, $ \widetilde{x_{\phi_{1b}}} = 1.07 $, $ \widetilde{y_{\phi_{2a}}} = 27.68 $ and $ \widetilde{y_{\phi_{2b}}} = 28.08 $.

    Figure 6.  The fuzzy solutions obtained by the proposed method (global).
    Figure 7.  The fuzzy solutions acquired by the proposed method (ordinate local interval $ [0, 30] $). And the black $ \alpha- $cuts of $ \widetilde{x} $: $ 0- $cut (continues lines), $ 1- $cut (dashed line); the blue $ \alpha- $cuts of $ \widetilde{y} $: $ 0- $cut (continues lines), $ 1- $cut (dashed line).

    Before the end of this section, we remark that the unique solution of the problem (4.1) on interval $ \left[\dfrac{\pi}{2}, \pi\right] $, $ \cdots $ can be found in the same way. Therefore, one can find the unique solution of the problem (4.1) for $ t > 0 $ via Algorithm (3.1).

    In this paper, inspired by Fatullayev et al. [14] and Dong et al. [13], by using the methods of steps and separating fuzzy items, we solved the implicit coupled systems of fuzzy fractional delay differential equations with fuzzy initial values and source functions (FFIDDC) (1.1). Under the conditions $ (H_1) $ and $ (H_2) $, and based on the concept of TFFs and examples in [16,17], we obtained existence and uniqueness of solution for the FFIDDC (1.1). We note that the solution is a triangular fuzzy function matrix which is composed of real functional matrices. Furthermore, an algorithm for solution procedure and an example for graphical confirmation of explicit solution were given.

    As Remark 1.1 mentioned, except for considering the problem (1.1) with Caputo fractional derivative, we will explore the problem of form (1.1) with fractional derivatives of Riemann-Liouville or Hadamard in the future. Recently, there are more and more researchers to explore the relevant (fractional) differentiable set-value problems and impulsive problems, such as Amrahov et al. [4] and Sun et al. [32]. Therefore, for further study, we can introduce the set-valued delay and the impulse into the FFIDDC (1.1), and extend the methods proposed in this paper to solve the new problems associated with set-values or impulsive elements.

    We are grateful to the anonymous referees and editors for their valuable comments and helpful suggestions to improve the quality of this paper.

    This work was partially supported by the Sichuan Science and Technology Program (2019YJ0541) the Opening Project of Sichuan Province University Key Laboratory of Bridge Non-destruction Detecting and Engineering Computing (2019QZJ03) and the Innovation Fund of Postgraduate, Sichuan University of Science & Engineering (y2020080).

    All authors declare no conflicts of interest in this paper.

    [1] Fujita T, Inoue K, Yamamoto S, et al. (1994) Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot 47: 208-215.
    [2] Fujita T, Inoue K, Yamamoto S, et al. (1994) Fungal metabolites. Part 12. Potent immunosuppressant, 14-deoxomyruiocin, (2S,3R,4R)-(E)-2-amino-3,4-dihydroxy-2- hydroxy- methyleicos-6-enoic acid and structure-activity relationships of myriocin derivatives. J Antibiot 47: 216-224.
    [3] Fujita T, Yoneta M, Hirose R, et al. (1995) Simple compounds, 2-alkyl-2- amino-1,3-propane-diols have potent immunosuppressive activity. Bioorg Med Chem Lett 5: 847-852. doi: 10.1016/0960-894X(95)00126-E
    [4] Adachi K, Kohara T, Nakao N, et al. (1995) Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immuno- suppressant, FTY720. Bioorg Med Chem Lett 5: 853-856. doi: 10.1016/0960-894X(95)00127-F
    [5] Fujita T, Hirose R, Yoneta M, et al. (1996) Potent immunosuppressants, 2-alkyl-2- aminopropane-1,3-diols. J Med Chem 39: 4451-4459. doi: 10.1021/jm960391l
    [6] Kiuchi M, Adachi K, Kohara T, et al. (2000) Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols. J Med Chem 43: 2946-2961. doi: 10.1021/jm000173z
    [7] Adachi K, Chiba K (2008) FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. Perspect Medicin Chem 1: 11-23.
    [8] Chiba K, Adachi K (2012) Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis. Pharmaceuticals 5:514-528. doi: 10.3390/ph5050514
    [9] Chiba K, Hoshino Y, Suzuki C, et al. (1996) FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc 28: 1056-1059.
    [10] Hoshino Y, Suzuki C, Ohtsuki M, et al. (1996) FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A. Transplant Proc 28: 1060-1061.
    [11] Kawaguchi T, Hoshino Y, Rahman F, et al. (1996) FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A. Transplant Proc 28: 1062-1063.
    [12] Chiba K. (2005) FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 108: 308-319. doi: 10.1016/j.pharmthera.2005.05.002
    [13] Matsuura M, Imayoshi T, Chiba K, Okumoto T (2000) Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats. Inflamm Res 49: 404-410. doi: 10.1007/s000110050608
    [14] Chiba K, Yanagawa Y, Masubuchi Y, et al. (1998) FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 160: 5037-5044.
    [15] Yanagawa Y, Sugahara K, Kataoka H, et al. (1998) FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 160: 5493-5499.
    [16] Brinkmann V. Pinschewer D, Chiba K, Feng L (2000) FTY720: A novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci 21: 49-52. doi: 10.1016/S0165-6147(99)01419-4
    [17] Brinkmann V, Davis MD, Heise CE, et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277: 21453-21457. doi: 10.1074/jbc.C200176200
    [18] Mandala S, Hajdu R, Bergstrom J, et al. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346-349. doi: 10.1126/science.1070238
    [19] Matloubian M, Lo CG, Cinamon G, et al. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427: 355-360. doi: 10.1038/nature02284
    [20] Spiegel S, Milstien S (2007) Functions of the multifaceted family od sphingosine kinases and some dose relatives. J Biol Chem 282: 2125-2129. doi: 10.1074/jbc.R600028200
    [21] Hannun YA, Obeid LM (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9: 139-150. doi: 10.1038/nrm2329
    [22] Pyne S, Pyne N (2000) Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors. Pharmacol Ther 88: 115-131. doi: 10.1016/S0163-7258(00)00084-X
    [23] Spiegel S (2000) Sphingosine 1-phosphate: A ligand for the EDG-1 family of G-protein-coupled receptors. Ann NY Acad Sci 905: 54-60.
    [24] Rivera J, Proia RL, Olivera A (2008) The alliance of shpingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 8: 753-763. doi: 10.1038/nri2400
    [25] Spiegel S, Milstien S (2011) The outs and the ins of shingosine-1-phosphate in immunity. Nat Rev Immunol 11: 403-415. doi: 10.1038/nri2974
    [26] Paugh SW, Payne SG, Barbour SE, et al. (2003) The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 554:189-193. doi: 10.1016/S0014-5793(03)01168-2
    [27] Chiba K, Matsuyuki H, Maeda Y, Sugahara K (2006) Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell Mol Immunol 3: 11-19.
    [28] Maeda Y, Matsuyuki H, Shimano K, et al. (2007) Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. J Immunol 178: 3437-3446. doi: 10.4049/jimmunol.178.6.3437
    [29] Pham TH, Okada T, Matloubian M, et al. (2008) S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 28: 122-133. doi: 10.1016/j.immuni.2007.11.017
    [30] Cyster JG (2005) Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23: 127-159. doi: 10.1146/annurev.immunol.23.021704.115628
    [31] Mitra P, Oskeritzian CA, Payne SG, et al. (2006) Role of ABCC1 in export of sphingosine- 1-phosphate from mast cells. Proc Natl Acad Sci USA 103: 16394-16399. doi: 10.1073/pnas.0603734103
    [32] Nishi T, Kobayashi N, Hisano Y et al. (2014) Molecular and physiological functions of sphingosine 1-phosphate transporters. Biochim Biophys Acta 1841: 759-765. doi: 10.1016/j.bbalip.2013.07.012
    [33] Mechtcheriakova D, Wlachos A, Sobanov J, et al. (2007) Sphingosine 1-phosphate phosphatase 2 is induced during inflammatory responses. Cell Signal 19: 748-760. doi: 10.1016/j.cellsig.2006.09.004
    [34] Peest U, Sensken SC, Andréani P, et al. (2008) S1P-lyase independent clearance of extracellular sphingosine 1-phosphate after dephosphorylation and cellular uptake. J Cell Biochem 104: 756-772. doi: 10.1002/jcb.21665
    [35] Zhao Y, Kalari SK, Usatyuk PV, et al. (2007) Intracellular generation of sphingosine 1-phosphate in human lung endothelial cells: role of lipid phosphate phosphatase-1 and sphingosine kinase 1. J Biol Chem 282: 14165-14177. doi: 10.1074/jbc.M701279200
    [36] Pappu R, Schwab SR, Cornelissen I, et al. (2007) Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316: 295-298. doi: 10.1126/science.1139221
    [37] Schwab SR, Pereira JP, Matloubian M, et al. (2005) Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309: 1735-1739. doi: 10.1126/science.1113640
    [38] Lo CG, Xu Y, Proia RL, Cyster JG (2005) Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med. 201: 291-301. doi: 10.1084/jem.20041509
    [39] Kiuchi M, Adachi K, Tomatsu A, et al. (2005) Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate. Bioorg. Med. Chem 13: 425-432. doi: 10.1016/j.bmc.2004.10.008
    [40] Matsuyuki H, Maeda Y, Yano K, et al. (2006) Involvement of sphingosine 1-phosphate (S1P) receptor type 1 and type 4 in migratory response of mouse T cells toward S1P. Cell Mol Immunol 3: 429-437.
    [41] Oo ML, Thangada S, Wu MT, et al. (2007) Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 282: 9082-9089. doi: 10.1074/jbc.M610318200
    [42] Ladi E, Yin X, Chtanova T, Robey EA (2006) Thymic microenvironments for T cell differentiation and selection. Nat Immunol 7: 338-343. doi: 10.1038/ni1323
    [43] Drennan MB, Elewaut D, Hogquist KA (2009) Thymic emigration: sphingosine-1-phosphate receptor-1-dependent models and beyond. Eur J Immunol 39: 925-930. doi: 10.1002/eji.200838912
    [44] Kato S, Schoefl GI (1989) Microvasculature of normal and involuted mouse thymus. Light- and electron-microscopic study. Acta Anat (Basel) 135: 1-11.
    [45] Kato S (1997) Thymic microvascular system. Microsc Res Tech 38: 287-299. doi: 10.1002/(SICI)1097-0029(19970801)38:3<287::AID-JEMT9>3.0.CO;2-J
    [46] Mori K, Itoi M, Tsukamoto N, et al. (2007) The perivascular space as a path of hematopoietic progenitor cells and mature T cells between the blood circulation and the thymic parenchyma. Int Immunol 19: 745-753. doi: 10.1093/intimm/dxm041
    [47] Zachariah MA, Cyster JG (2010) Neural crest-derived pericytes promote egress of mature thymocytes at the corticomedullary junction. Science 328: 1129-1135. doi: 10.1126/science.1188222
    [48] Cyster JG, Schwab SR (2012) Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 30: 69-94. doi: 10.1146/annurev-immunol-020711-075011
    [49] Yagi H, Kamba R, Chiba K, et al. (2000) Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol 30:1435.
    [50] Maeda Y, Yagi H, Takemoto K, et al. (2014) S1P lyase in thymic perivascular space promotes egress of mature thymocytes via up-regulation of S1P receptor 1. Int Immunol 26: 245-255. doi: 10.1093/intimm/dxt069
    [51] Allende ML, Dreier JL, Mandala S, Proia RL (2004) Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 279: 15396-15401. doi: 10.1074/jbc.M314291200
    [52] Saba JD, Hla T (2004) Point-counterpoint of sphingosine 1-phosphate metabolism. Circ Res 94: 724-734. doi: 10.1161/01.RES.0000122383.60368.24
    [53] Breart B, Ramos-Perez WD, Mendoza A, et al. (2011) Lipid phosphate phosphatase 3 enables efficient thymic egress. J Exp Med 208: 1267-1278. doi: 10.1084/jem.20102551
    [54] Vogel P, Donoviel MS, Read R, et al. (2009) Incomplete inhibition of sphingosine 1-phosphate lyase modulates immune system function yet prevents early lethality and non-lymphoid lesions. PLoS One 4:e4112.
    [55] Borowsky AD, Bandhuvula P, Kumar A, , et al. (2012) Sphingosine-1-phosphate lyase expression in embryonic and adult murine tissues. J Lipid Res 53: 1920-1931. doi: 10.1194/jlr.M028084
    [56] Suzuki S, Li XK, Enosawa S, and Shinomiya T (1996) A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes. Immunology 89:518-23. doi: 10.1046/j.1365-2567.1996.d01-777.x
    [57] Nagahara Y, Enosawa S, Ikekita M, et al. (2000) Evidence that FTY720 induces T cell apoptosis in vivo. Immunopharmacology 48:75-85. doi: 10.1016/S0162-3109(00)00181-8
    [58] Luo ZJ, Tanaka T, Kimura F, Miyasaka M (1999) Analysis of the mode of action of a novel immunosuppressant FTY720 in mice. Immunopharmacology. 41:199-207. doi: 10.1016/S0162-3109(99)00004-1
    [59] Sugito K, Koshinaga T, Inoue M, et al. (2005) The effect of a novel immunosuppressant, FTY720, in mice without secondary lymphoid organs. Surg Today 35:662-7. doi: 10.1007/s00595-005-3011-x
    [60] Maeda Y, Seki N, Sato N, et al. (2010) Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow. Int Immunol 22: 515-525. doi: 10.1093/intimm/dxq036
    [61] Webb M, Tham CS, Lin FF, et al. (2004) Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 153: 108-121. doi: 10.1016/j.jneuroim.2004.04.015
    [62] Kataoka H, Sugahara K, Shimano K, et al. (2005) FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2: 439-448.
    [63] Balatoni B, Storch MK, Swoboda EM, et al. (2007) FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 74: 307-316. doi: 10.1016/j.brainresbull.2007.06.023
    [64] Foster CA, Howard LM, Schweitzer A, et al. (2007) Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: Consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323: 469-475. doi: 10.1124/jpet.107.127183
    [65] Brinkmann V (2007) Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 115: 84-105. doi: 10.1016/j.pharmthera.2007.04.006
    [66] Chiba K, Kataoka H, Seki N, et al. (2011) Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis. Int Immunopharmacol 11: 366-372. doi: 10.1016/j.intimp.2010.10.005
    [67] Langrish CL, Chen Y, Blumenschein WM, et al. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201: 233-240. doi: 10.1084/jem.20041257
    [68] Komiyama Y, Nakae S, Matsuki T, et al. (2006) IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 177: 566-573. doi: 10.4049/jimmunol.177.1.566
    [69] Stromnes IM, Cerretti LM, Liggitt D, et al. (2008) Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells. Nat Med 14: 337-342. doi: 10.1038/nm1715
    [70] Seki N, Maeda Y, Kataoka H, et al. (2013) Role of sphingosine 1-phosphate (S1P) receptor 1 in experimental autoimmune encephalomyelitis. I. S1P-S1P1 axis induces migration of Th1 and Th17 cells. Pharmacology & Pharmacy 4: 628-637.
    [71] Brinkmann V (2009) FTY720 (fingolimod) in Multiple Sclerosis: Therapeutic effects in the immune and the central nervous system. Br J Pharmacol 158: 1173-1182. doi: 10.1111/j.1476-5381.2009.00451.x
    [72] Choi JW, Gardell SE, Herr DR, et al. (2011) FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 108: 751-756. doi: 10.1073/pnas.1014154108
    [73] Seki N, Kataoka H, Sugahara K, et al. (2013) Role of sphingosine 1-phosphate (S1P) receptor 1 in experimental autoimmune encephalomyelitis. II. S1P-S1P1 axis induces pro-inflammatory cytokine production in astrocytes. Pharmacology & Pharmacy 4: 638-646.
    [74] Matsuura M, Imayoshi T, Okumoto T (2000) Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. Int J Immunopharmacol 22: 323-331. doi: 10.1016/S0192-0561(99)00088-0
    [75] Tsunemi S, Iwasaki T, Kitano S, et al. (2010) Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model. Clin Immunol 136: 197-204. doi: 10.1016/j.clim.2010.03.428
    [76] Okazaki H, Hirata D, Kamimura T, et al. (2002) Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol 29: 707-716.
    [77] Wenderfer SE, Stepkowski SM, Braun MC (2008) Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist. Kidney Int 74: 1319-1326. doi: 10.1038/ki.2008.396
    [78] Alperovich G, Rama I, Lloberas N, et al. (2007) New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus 16: 18-24. doi: 10.1177/0961203306073136
    [79] Mizushima T, Ito T, Kishi D, et al. (2004) Therapeutic effects of a new lymphocyte homing reagent FTY720 in interleukin-10 gene-deficient mice with colitis. Inflamm Bowel Dis 10: 182-192. doi: 10.1097/00054725-200405000-00002
    [80] Deguchi Y, Andoh A, Yagi Y, et al (2006) The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice. Oncol Rep 16: 699-703.
    [81] Daniel C, Sartory N, Zahn N, et al. (2007) FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol 178: 2458-2468. doi: 10.4049/jimmunol.178.4.2458
    [82] Radi ZA, Heuvelman DM, Masferrer JL, et al (2011) Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohn's disease model. Dig Dis Sci 56: 2283-2291. doi: 10.1007/s10620-011-1628-8
    [83] Budde K, Schmouder RL, Brunkhorst R, et al. (2002) Human first trail of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 13: 1073-1083.
    [84] Budde K, Schmouder RL, Nashan B, et al. (2003) Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant 3: 846-854. doi: 10.1034/j.1600-6143.2003.00130.x
    [85] Kahan BD, Karlix JL, Ferguson RM, et al. (2003) Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation 76: 1079-1084. doi: 10.1097/01.TP.0000084822.01372.AC
    [86] Martin R, McFarland HF, McFarlin DE (1992) Immunological aspects of demyelinating diseases. Annu Rev Immunol 10: 153-187. doi: 10.1146/annurev.iy.10.040192.001101
    [87] Kornek B, Storch MK, Weissert R, et al. (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157: 267-276. doi: 10.1016/S0002-9440(10)64537-3
    [88] Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46: 907-911.
    [89] Goodkin DE, Reingold S, Sibley W, et al. (1999) Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: Reporting extended results from phase III clinical trials. National Multiple Sclerosis Society Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Ann Neurol 46: 132-134.
    [90] Kappos L, Antel J, Comi G, et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Eng J Med 355: 1124-1140. doi: 10.1056/NEJMoa052643
    [91] Mehling M, Lindberg R, Raulf F, et al. (2011) Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 75: 403-410.
    [92] Kappos L, Radue EW, O’Connor P, et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387-401. doi: 10.1056/NEJMoa0909494
    [93] Saida T, Kikuchi S, Itoyama Y, et al. (2012) A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler 18:1267-1277.
    [94] Kira J, Itoyama Y, Kikuchi S, et al. (2014) Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurology 14: 21. doi: 10.1186/1471-2377-14-21
    [95] Cohen JA, Barkhof F, Comi G, et al. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402-415. doi: 10.1056/NEJMoa0907839
    [96] Deogracias R, Yazdani M, Dekkers MP, et al (2013) Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci USA 109: 14230-14235.
    [97] Igarashi J, Erwin PA, Dantas AP, et al. (2003) VEGF induces S1P1 receptors in endothelial cells: implications for crosstalk between sphingolipid and growth factors receptors. Proc Natl Acad Sci USA 100: 10664-10669. doi: 10.1073/pnas.1934494100
    [98] Sanna MG, Liao J, Jo E, et al. (2004). Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279: 13839-13848. doi: 10.1074/jbc.M311743200
    [99] Shimizu H, Takahashi M, T. Kaneko T et al. (2005) KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 111: 222-229. doi: 10.1161/01.CIR.0000152101.41037.AB
    [100] Hamada M, Nakamura M, Kiuchi M et al. (2010) Removal of sphingosine 1-phosphate receptor-3 (S1P3) agonism is essential, but inadequate to obtain immunomodulating 2-aminopropane-1,3-diol S1P1 agonists with reduced effect on heart rate. J Med Chem 53: 3154-3168. doi: 10.1021/jm901776q
    [101] Hale JJ, Lynch, CL, Neway WE, et al. (2004) A unique utilization of high throughput screening leads to afford selective, orally bioavailable 1-benzyl-3-carboxyazetidine S1P1 receptor agonists. J Med Chem 47: 6662-6665. doi: 10.1021/jm0492507
    [102] Vachal P, Toth LM, Hale JJ, et al. (2006) Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor. Bioorg Med Chem Lett 16: 3684-3687. doi: 10.1016/j.bmcl.2006.04.064
    [103] Foss FW, Snyder AH, Davis MD, et al. (2007) Synthesis and biological evaluation of gammma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem 15: 663–677.
    [104] Hanessian S, Charron G, Billich A, et al. (2007) Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors. Bioorg Med Chem Lett 17: 491-494. doi: 10.1016/j.bmcl.2006.10.014
    [105] Pan S, Gray NS, Gao W, et al. (2013) Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med Chem Lett 4: 333-337. doi: 10.1021/ml300396r
    [106] Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. (2012) The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol 167: 1035-1047. doi: 10.1111/j.1476-5381.2012.02061.x
    [107] Selmaj K, Li DK, Hartung HP, et al. (2013) Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 12: 756-767. doi: 10.1016/S1474-4422(13)70102-9
    [108] Biswal S, Veldandi UK, Derne C, et al. (2014) Effect of oral siponimod (BAF312) on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive in healthy female subjects. Int J Clin Pharmacol Ther Aug 27. [Epub ahead of print]
    [109] Olsson T, Boster A, Fernández O, et al (2014) Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry 85: 1198-1208. doi: 10.1136/jnnp-2013-307282
    [110] Vaclavkova A, Chimenti S, Arenberger P, et al. (2014) Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet pii: S0140-6736: 60803-60805.
    [111] Mazurais D, Robert P, Gout B, et al. (2002) Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem 50: 661-670. doi: 10.1177/002215540205000507
    [112] Lukas S, Patnaude L, Haxhinasto S, et al. (2014) No differences observed among multiple clinical S1P1 receptor agonists (functional antagonists) in S1P1 receptor down-regulation and degradation. J Biomol Screen 19: 407-416. doi: 10.1177/1087057113502234
    [113] Oo ML, Chang SH, Thangada S, et al. (2011) Engagement of S1P1-degradative mechanisms leads to vascular leak in mice. J Clin Invest 121: 2290-2300. doi: 10.1172/JCI45403
    [114] Violin JD, Crombie AL, Soergel DG, et al. (2014) Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci 35: 308-316. doi: 10.1016/j.tips.2014.04.007
  • This article has been cited by:

    1. Martha Álvarez–Ramírez, Johanna D. García–Saldaña, Mario Medina, Global Dynamics and Integrability of a Leslie-Gower Predator–Prey Model with Linear Functional Response and Generalist Predator, 2024, 23, 1575-5460, 10.1007/s12346-024-01155-0
    2. Cahit Köme, Yasin Yazlik, Stability, bifurcation analysis and chaos control in a discrete predator–prey system incorporating prey immigration, 2024, 70, 1598-5865, 5213, 10.1007/s12190-024-02230-0
    3. Maurıicio F. S. Lima, Jaume Llibre, Hopf bifurcation for a class of predator-prey system with small immigration, 2024, 32, 2688-1594, 4604, 10.3934/era.2024209
  • Reader Comments
  • © 2014 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(12683) PDF downloads(2072) Cited by(8)

Figures and Tables

Figures(5)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog